CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models

CONCLUSIONS: CD276- and CD276/FGFR4-directed CAR Ts showed effective RMS cell killing in vitro and eradication of CD276high RMS tumors in vivo. CD276low tumors escaped the therapy highlighting a correlation between antigen density and effectiveness. FGFR4-CAR Ts showed specific killing in vitro but could only delay RMS growth in vivo. Our results demonstrate that combined expression of CD276-CAR with other CAR does not reduce its benefit. Introducing immunotherapy with CD276-CAR Ts in RMS seems to be feasible and promising, although CAR constructs design and target combinations have to be further improved to eradicate tumors with low target expression.PMID:37924157 | PMC:PMC10625270 | DOI:10.1186/s13046-023-02838-3

Source: Cell Research - November 4, 2023 Category: Cytology Authors: Andrea Timpanaro Caroline Piccand Dzhangar Dzhumashev Stenija Anton-Joseph Andrea Robbi Janine Moser Jochen R össler Michele Bernasconi Source Type: research